PsychRounds: The Psychiatry Podcast Topiramate (Topamax)
Jan 28, 2026
A concise run-through of topiramate’s psychiatric roles and origins. They cover its FDA history, mechanisms, dosing and interactions. Listeners hear trial data on alcohol use disorder, eating disorders, and antipsychotic-related weight mitigation. Cognitive and other notable adverse effects are highlighted, plus where evidence is mixed or lacking.
AI Snips
Chapters
Transcript
Episode notes
Topiramate's Psychiatric Role Is Largely Off-Label
- Topiramate has no FDA psychiatric approvals but found off-label psychiatric uses, notably for alcohol use disorder.
- Early open-label mania trials looked promising but randomized data failed to show benefit, so guidelines do not recommend it for bipolar disorder.
Multiple Mechanisms Explain Effect And Side Effects
- Topiramate works on multiple targets: blocks voltage-gated sodium channels, enhances GABA, modulates AMPA/kainate glutamate receptors, and weakly inhibits carbonic anhydrase.
- These effects plausibly explain its benefit in alcohol use disorder and account for side effects like metabolic acidosis and kidney stones.
Dosing, Formulation, And Interaction Tips
- Start low and titrate: typical initiation is 25–50 mg daily and usual psychiatric doses range 100–200 mg/day with an FDA max of 400 mg/day.
- Use extended-release once daily when possible, adjust for renal impairment, and watch CYP interactions (notably OCPs and CYP3A4 substrates).